NCT07321951Active, not recruitingPhase 2
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 201 (actual)
- First submitted
- 21 Dec 2025
- Start date
- 9 Jan 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07321951
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 201
- From 9 Jan 2026 to the primary completion date, Jun 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A history of spring keratoconjunctivitis and/or atopic keratoconjunctivitis within 6 months prior to screening.
- Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
Other illness
- Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
- Has malignancy or has a history of malignancy.
- Hypersensitivity to the study drug or any ingredient in the study drug.
Other
- Females who are pregnant or lactating.
Who the study is looking for
- At the time of signing the informed consent, the subjects are ≥18 years old and ≤75 years old, male or female.
- The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
- Topical emollients are applied at a stable dose twice daily for at least 7 days before the first dose in the run-in phase and continued for the duration of the study.
- Have atopic dermatitis at the time of screening and have an investigator-assessed history of atopic dermatitis for at least 1 year before screening.
- Have moderate to severe atopic dermatitis during the screening period and on the day of the first dose.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatology Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Hangzhou Third People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.